Out-Licensing Agreements - Deferred Revenue (Details) $ in Thousands |
9 Months Ended | 21 Months Ended |
---|---|---|
Sep. 30, 2022
USD ($)
|
Sep. 30, 2022
USD ($)
|
|
Collaborative agreements | ||
Long-term Deferred Revenue | $ 14,198 | $ 14,198 |
Additions | 26,290 | |
Balance at end of period | 26,290 | 26,290 |
Territory License - Rilonacept | Huadong rilonacept | ||
Collaborative agreements | ||
Long-term Deferred Revenue | 12,000 | 12,000 |
Additions | 12,000 | |
Balance at end of period | 12,000 | 12,000 |
Territory License - Rilonacept | Huadong rilonacept | License and collaboration revenue | ||
Collaborative agreements | ||
Revenue recognized | 0 | |
Worldwide License - Vixarelimab | Genentech | ||
Collaborative agreements | ||
Additions | 14,290 | |
Balance at end of period | $ 14,290 | $ 14,290 |